06.25.26 -- An Inside View Of The Clinical Trials Technology Congress

Learn how subtle influences derail decisions and discover proven safeguards that promote transparency, accountability, and shared ownership for better trial outcomes.

Escape US site bottlenecks by moving oncology research to Asia. Discover how you can connect with diverse patient pools at premier research centers with lower overhead.

Move drug development into the modern era with a CRO that offers assay development and validation, bioanalytical testing, sample prep, and more.

Explore how you can obtain end-to-end injectable services with a company offering a comprehensive approach to providing easy-to-use, patient-centric therapies.

A new biomarker risk score developed by the Pulmonary Fibrosis Foundation's PROLIFIC consortium could serve as the latest prognostic or predictive tool in clinical trials and care. for those diagnosed with idiopathic pulmonary fibrosis (IPF).

In March, the US FDA sent thousands of reminders to submit clinical trial results to ClinicalTrials.gov or complete the federal-mandated National Library of Medicine quality control review process.

Machine learning is transforming clinical trial reporting by replacing static enrollment forecasts with dynamic, real-time milestone projections that improve predictability and oversight.

Choose the right IRT partner for complex master protocols. Learn how adaptive randomization expertise and flexible technology reduce disruption and keep trials execution-ready.

New FDA/EMA principles align global expectations for AI in drug trials, emphasizing transparency, human-centric design, and risk-based governance to ensure data integrity and patient safety.

Explore how the latest regulatory updates transform real-world data into a credible evidentiary pathway. Learn the new standards for data reliability and hybrid study design.

A clear guide to U.S. coverage, regulation, and reimbursement: who decides care, how products gain access, and how policy and financing shape cost, value, and patient access.

Oversight in 2026 requires adaptability as AI, consent standards, and regulatory uncertainty challenge sponsors and IRBs to balance ethics with innovation through proactive planning and collaboration.